Welcome to our dedicated page for ARCELLX SEC filings (Ticker: ACLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Arcellx, Inc. (NASDAQ: ACLX), a clinical-stage biotechnology company developing cell therapies and immunotherapies for cancer and other incurable diseases. Through these filings, investors can review how Arcellx reports its financial condition, collaboration revenue, research and development spending, and progress toward potential commercialization.
Arcellx uses periodic and current reports to disclose key information. For example, the company files Form 8-K to furnish press releases announcing quarterly financial results, as reflected in 8-K filings tied to results for quarters ended June 30 and September 30, 2025. These filings describe collaboration revenue associated with its partnership activities, research and development expenses related to clinical and preclinical programs, general and administrative expenses, and net losses as the company advances its pipeline.
In addition to 8-Ks, investors can use this page to find Arcellx’s annual reports on Form 10-K and quarterly reports on Form 10-Q when available. These documents typically provide detailed discussions of the company’s lead BCMA-directed CAR T-cell therapy, anitocabtagene autoleucel (anito-cel), its Phase 2 iMMagine-1 and Phase 3 iMMagine-3 studies in relapsed or refractory multiple myeloma, regulatory designations, and its global strategic collaboration with Kite, a Gilead Company.
Stock Titan enhances these filings with AI-powered summaries that highlight key points such as revenue trends, R&D and G&A dynamics, cash runway disclosures, and material clinical or regulatory updates. Users can also review insider transaction reports on Form 4, proxy statements on Form DEF 14A, and other relevant submissions as they appear in the SEC’s EDGAR system. Together, these resources help investors and researchers quickly interpret Arcellx’s regulatory disclosures and understand the financial and operational context behind ACLX.
Arcellx, Inc. supplements its Schedule 14D-9 to disclose updates to the proposed acquisition by Ravens Sub, Inc./Gilead Sciences.
The filing confirms an Offer extension to April 24, 2026, HSR waiting‑period expiration on March 31, 2026, additional international filings, and newly filed shareholder lawsuits and demand letters challenging the disclosures.
Ravens Sub, Inc., a wholly owned subsidiary of Gilead Sciences, Inc., amended its Schedule TO to report results and updates to its tender offer for all outstanding shares of Arcellx, Inc. The Offer pays $115.00 per share in cash plus one contingent value right (a CVR) that may pay $5.00 on March 31, 2030 if cumulative worldwide sales of anito-cel exceed $6.0 billion on or prior to December 31, 2029. The HSR waiting period expired on March 31, 2026. As of 5:00 p.m. ET on March 31, 2026, approximately 4,389,763 shares (about 7.5% of outstanding) were validly tendered. Parent extended the Offer expiration to 5:00 p.m. ET on April 24, 2026. The filing discloses related antitrust notifications in Germany, Austria and Australia and two New York stockholder lawsuits and multiple demand letters alleging disclosure deficiencies.
Arcellx Inc Schedule 13G/A: The Vanguard Group filed Amendment No. 2 reporting 0 shares beneficially owned of Arcellx common stock following an internal realignment. The filing states certain Vanguard subsidiaries will report separately in reliance on SEC Release No. 34-39538 and that Vanguard no longer is deemed to beneficially own those securities. The amendment is dated 03/26/2026 and references the realignment on 01/12/2026.
Arcellx, Inc.’s Chief Financial Officer, Michelle Gilson, reported a bona fide gift of 5,000 shares of Common Stock. On March 17, 2026, she transferred these shares for no consideration to a family charitable foundation.
After the gift, she directly owns 28,938 shares of Arcellx common stock and the foundation holds 5,000 shares indirectly attributed to her. She serves as President of the foundation and retains voting and investment power over all securities owned by it, so her overall economic exposure remains largely intact despite this non-market transfer.
Arcellx, Inc. recommends that stockholders accept the Offer by Ravens Sub, Inc./Gilead: $115.00 per share in cash plus one CVR (each CVR gives the holder a contingent $5.00 payment payable March 31, 2030 if cumulative worldwide sales of anito-cel exceed $6.0 billion on or prior to December 31, 2029).
The Company Board unanimously approved the Merger Agreement and recommends tendering shares. The Offer is scheduled to expire one minute after 11:59 p.m. ET on April 2, 2026. Shares issued and outstanding were 58,672,448 as of March 3, 2026.
Gilead Sciences, through its wholly owned subsidiary Ravens Sub, Inc., is offering to acquire Arcellx, Inc. by purchasing all outstanding common shares at $115.00 per share in cash plus one contingent value right (CVR) that can pay $5.00 on March 31, 2030 if cumulative worldwide sales of anito-cel exceed $6.0 billion on or prior to December 31, 2029.
The Schedule TO states 58,672,448 shares were outstanding as of March 3, 2026, and the Offer is not subject to a financing condition. The merger agreement and offer documents are filed as exhibits.
Arcellx Inc. Schedule 13G/A discloses that T. Rowe Price Investment Management, Inc. beneficially owned 2,653,848 shares of Arcellx common stock, representing 4.5% of the class as of 02/28/2026. The filing states sole voting power of 2,503,059 shares and sole dispositive power of 2,647,494. Item 5 notes ownership of 5 percent or less of a class.
FMR LLC reports beneficial ownership of 309,117.46 shares (0.5%) of Arcellx Inc common stock. The amendment to Schedule 13G/A lists sole dispositive power for FMR LLC of 309,117.46 shares and shows Abigail P. Johnson with dispositive power for the same share amount.
The filing cites addresses for FMR LLC and Arcellx and is signed and dated 03/05/2026.
Arcellx, Inc. director and officer Rami Elghandour reported a Form 4 showing a bona fide gift of 101,164 shares of common stock on March 4, 2026. The shares were transferred for no consideration to a family charitable foundation where he serves as President and has voting and investment power over the foundation’s holdings.
After the gift, Elghandour directly held 174,887 shares. The filing also lists indirect holdings by two spousal lifetime access non-grantor trusts, with 198,000 and 218,500 shares, and by the family charitable foundation with 101,164 shares, with disclaimers of beneficial ownership except to the extent of any pecuniary interest.
Arcellx, Inc. director and officer Rami Elghandour reported multiple stock transactions. On February 27, 2026, he completed an open-market, broker-assisted sale of 89,916 shares of common stock at a weighted average price of $113.9204 per share to cover tax withholding obligations from previously vested restricted stock units.
Following this sale, he held 276,051 shares directly. Earlier in January 2026, he acquired 55,991, 53,098 and 55,459 shares of common stock through exercises or conversions of derivative securities at $0.0000 per share. In addition, 198,000 shares and 218,500 shares are held indirectly in spousal lifetime access non-grantor trusts, where he may be deemed to have beneficial ownership but disclaims ownership except for any pecuniary interest.